Press Center: Legal updates

From 1 September 2026, new rules for calculating remuneration for employees who are the authors of employee inventions, utility models and industrial designs will come into force. The document fundamentally changes the approach to such payments.

The Russian Ministry of Health’s draft law “On Amending Certain Legislative Acts of the Russian Federation…” (“the Draft Law”), concerning changes to the control of the circulation of medicinal products has been published on the federal portal for draft regulatory acts.

The past days have been marked by landmark rulings from the Russian Supreme and Constitutional Courts, decisions that will influence future case law and the pharmaceutical market as a whole.

On 24 November 2025, the Delhi High Court issued a judgment in a major patent dispute Medilabo Rfp Inc. v. The Controller of Patents C.A. (Comm.Ipd-Pat) 16/2024, concerning the patent eligibility of a drug for neurodegenerative diseases.

In June 2024, the pharmaceutical industry faced a new practice by the Federal Antimonopoly Service (FAS), which began to consistently recognize the introduction of generic drugs onto the market as unfair competition.

On August 7, 2025, a draft law “On Amending the Federal Law ‘On Protection of Competition’” (hereinafter, the “Draft Law”) was published. Prepared by the Federal Antimonopoly Service (hereinafter, the “FAS”), it aims to significantly narrow the scope of antitrust immunities concerning the results of intellectual activity.

On 7 July 2025, Federal Law No. 214-FL «On Amendments to Part Four of the Civil Code of the Russian Federation» was published. This law introduces the following significant changes to the provisions on the recovery of compensation for infringement of exclusive rights to intellectual property and means of individualisation equivalent thereto.

The State Duma is considering the bill No. 818556-8 “On Amendments to Part Four of the Civil Code of the Russian Federation” (the “Bill”), the authors of which propose to amend the procedure for making decisions on the use of inventions, utility models and industrial designs (“Objects of patent rights”) established by Article 1360 of the Civil Code of the Russian Federation.

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.

On 27.09.2024 the Decree of the Government the Russian Federation No. 1278 was published. This Decree amends for the Regulation on Patent and Other Fees for Legally Significant Actions.